The honest answer up front: this is not a choice between two treatment options. It sets a body of approved, guideline-backed therapy against a single investigational peptide supported by a handful of small early-phase studies. Standard care is imperfect but tested in randomised trials, available, and monitored, while ARA-290 holds no marketing authorisation in any major jurisdiction and has never been tested head to head against any approved neuropathy medicine.
| Criteria | Standard treatments | ARA-290 (cibinetide) |
|---|---|---|
| Regulatory status | Approved for neuropathic pain indications | Investigational, no marketing authorisation |
| Evidence level | Human clinical, decades of randomised data | Small phase 2 only, enrolment in the tens |
| Study scale and length | Hundreds of patients, weeks to months | Tens of patients, about four weeks |
| Reported effect | NNT about 4 for tricyclics, 6 to 8 for gabapentinoids and duloxetine | Improved symptom scores and corneal nerve measures, unconfirmed |
| Lawful access | Prescription and pharmacy supply | Registered trial or sanctioned expanded access only |
ARA-290 carries no marketing authorisation in any major jurisdiction and has never been compared head to head with an approved neuropathy medicine, while standard agents rest on decades of randomised data placing the number needed to treat for fifty percent pain relief at roughly four for tricyclics and six to eight for gabapentinoids and duloxetine.
No medicine anywhere holds an approval reading "for the treatment of small fiber neuropathy." The approvals clinicians rely on were granted for painful diabetic peripheral neuropathy and postherpetic neuralgia, so their use in small fiber neuropathy extends that evidence rather than following a licensed indication of its own. What national and specialty guidance converges on is a short list of classes with modest, well-quantified returns.
Established drug therapy for small fiber neuropathy rests on gabapentinoids, duloxetine, tricyclics, and topical capsaicin or lidocaine, none carrying an approval that names small fiber neuropathy itself, and pooled trial data put most patients in partial relief rather than resolution.
Treating the two as rival choices misstates what each label certifies. A marketing authorisation is a regulator's finding, after review of the full dossier, that benefit outweighs risk for a defined population, that the product can be made to a consistent standard, and that its labelling describes dose, contraindications, interactions, and known harms accurately enough for a prescriber to act on. Investigational status certifies none of that.
Across therapeutic areas roughly half or fewer of compounds that succeed in phase 2 go on to succeed in phase 3, with pain and central nervous system indications among the worst performers, and ARA-290's record stops at small phase 2 work with no confirmatory programme reported.
The mechanistic contrast is the most genuinely interesting part of this comparison and the part most often overstated. ARA-290 is an eleven amino acid sequence corresponding to the helix B domain of erythropoietin, a face of the molecule that does not contact the classical erythropoietin receptor, and it is proposed instead to engage a repair receptor expressed on injured tissue rather than on erythroid precursors. Every approved option acts on the pain signal, which puts ARA-290 in a category that does not yet clinically exist.
Every approved neuropathy agent is symptomatic rather than disease-modifying, and the ARA-290 repair mechanism remains a mechanistic hypothesis carried by preclinical work, never confirmed to change nerve structure or function in an adequately powered human trial.
Endpoints are where the comparison turns concrete. The published human work on ARA-290 leaned on corneal nerve fiber imaging and patient-completed symptom lists over roughly four weeks, while the pivotal trials behind pregabalin and duloxetine ran a prespecified pain score in hundreds of patients. A structural surrogate and a symptom claim are not interchangeable, and that gap decides what a regulator is able to conclude.
| Criteria | ARA-290 phase 2 studies | Pivotal trials of approved agents |
|---|---|---|
| Enrolment | Tens, largest near sixty participants | Hundreds per trial |
| Duration | About four weeks of daily subcutaneous dosing | Roughly five to twelve weeks |
| Primary measure | Symptom screening lists, corneal nerve fiber measures | Prespecified patient-reported pain score |
| Supporting measures | Quantitative sensory testing, six-minute walk distance | Responder rates at thirty and fifty percent pain reduction |
Corneal nerve fiber imaging remains a surrogate with no established link between four-week structural change and durable symptomatic benefit, whereas the approvals for pregabalin and duloxetine rested on prespecified patient-reported pain scores in trials enrolling hundreds of patients over five to twelve weeks.
Set the two literatures side by side and the asymmetry is stark rather than marginal. Total human exposure to ARA-290 across its published controlled studies reaches low hundreds of participants at most, concentrated in a small number of centres and tied closely to a single developer and a narrow circle of collaborating investigators. The approved agents sit at the opposite end, pooled in reviews and meta-analyses of thousands of randomised participants and backed by many millions of patient-years of real-world use.
More than a decade after the first human results, ARA-290 has no reported confirmatory trial and no independent replication, while pregabalin, gabapentin, duloxetine, and amitriptyline each carry multiple pivotal trials, pooled analyses of thousands of randomised participants, and millions of patient-years of postmarketing exposure that can surface a one-in-ten-thousand harm.
One route in current practice genuinely changes the disease rather than the sensation, and it is not a drug aimed at nerve repair. It is finding and treating whatever is damaging the fibers. A thorough workup identifies a cause in roughly half of cases, sometimes more in specialist centres.
A randomised placebo-controlled trial of intravenous immunoglobulin in idiopathic small fiber neuropathy failed to meet its primary endpoint despite strong rationale and encouraging open-label reports, and cause-directed workup, which finds a treatable driver in roughly half of cases, remains the only established route to disease modification.
Published trials describe ARA-290 as generally well tolerated over short courses, with headache, fatigue, and gastrointestinal upset reported most often, injection site pain no more frequent than with placebo, and a small number of serious adverse events among participants receiving the peptide. That record supports less than it appears to, because a few hundred people dosed for about four weeks can rule out common effects and gross laboratory disturbance and nothing rarer or longer.
The ARA-290 safety record spans a few hundred participants dosed for roughly four weeks, which leaves events rarer than one in a thousand, exposures beyond a month, and effects in frail or heavily co-medicated patients unmeasured rather than ruled out.
The gap between a compound studied under protocol and a vial bought online is enormous and frequently underestimated. Independent analyses of peptides sold through grey-market channels have repeatedly found contents that do not match the label: wrong compound, wrong concentration, purity far below the claim, undeclared additives, and bacterial endotoxin. Research-use-only labelling is a disclaimer that the material was never manufactured to pharmaceutical standards, not a quality tier.
Material sold as ARA-290 outside a registered trial carries no release testing for identity, potency, purity, or sterility, and independent testing of grey-market peptides has repeatedly returned wrong compounds, under-dosed material, undeclared additives, and bacterial endotoxin.
Cost comparisons mislead here unless the products being compared are actually comparable, and they are not. Gabapentin, amitriptyline, nortriptyline, duloxetine, and now pregabalin are long off patent and rank among the least expensive medicines in routine use, dispensed by a pharmacy with a prescriber's time part of the package. ARA-290 has no price because it has no market.
| Criteria | Approved neuropathy drugs | ARA-290 |
|---|---|---|
| Typical cost | Often a few dollars a month as generics | No market price, no lawful sale |
| Coverage | Insurance or national scheme, subject to the label indication | None |
| Access route | Prescription and pharmacy dispensing | Registered trial or sanctioned expanded access |
| Included oversight | Prescriber assessment, monitoring, and recourse | None outside a trial |
Generic gabapentin, amitriptyline, nortriptyline, and duloxetine cost a few dollars a month with dispensing and prescriber oversight included, while ARA-290 has exactly two lawful access routes, a registered clinical trial or a regulator-sanctioned expanded access arrangement, and no purchasable price at all.
Durability separates the two claims more sharply than efficacy does. Every approved option is openly symptomatic: pain returns over days to weeks once a gabapentinoid or an antidepressant stops, which is why these are continuing therapies and why tapering rather than abrupt withdrawal is described in prescribing guidance. A repair-directed compound implicitly claims something different, that structural recovery persists after dosing ends.
No published ARA-290 study followed participants long enough after dosing to show a maintained separation from placebo, so the durability of any structural benefit is genuinely unanswered, while every approved agent openly delivers relief only for as long as treatment continues, with high-concentration capsaicin lasting about three months per application.
Educational use only. This article describes what the published scientific and clinical literature reports about ARA-290. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
